Hematide: Preliminary Phase II data

Preliminary data from an open-label, Phase II trial in 114 hemodialysis patients not receiving erythropoiesis stimulating agent (ESA) treatment showed that both doses of monthly IV Hematide (0.04 and 0.08 mg/kg) increased hemoglobin levels to the target range of 11-12 g/dL at week 12 and maintained them through the 28-week trial. The active control of 50 U/kg IV epoetin alfa thrice weekly also achieved the target. Rates of serious adverse events, including arteriovenous thrombosis, vitreous hemorrhage and hypertension, were not significantly different among the treatment groups. Data were presented at the American Society of Nephrology meeting in San Diego. ...